<?xml version="1.0" encoding="UTF-8"?>
<p id="par0095">Many patients may be immunocompromised due to the underlying malignancy or anticancer therapy or primitive immunodeficiencies and are at higher risk of developing infections. As with other infections, the risk of COVID-19 is increased in these patients. Clinical studies in cancer patients report a higher risk of infection than in a non-cancerous population (median age 66 years) ([
 <xref rid="bib0235" ref-type="bibr">47</xref>]). However, some data suggest that there is no greater multiorgan compromise from SARS-CoV-2 in immunocompromised individuals as a consequence of chemotherapy ([
 <xref rid="bib0240" ref-type="bibr">48</xref>])
</p>
